Gulf Drug Officially Launches EOFlow’s Wearable Insulin Pump “EOPatch” in the UAE

EOFlow Co., Ltd. today reported that its GCC partner, GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) officially announced the launch of its tubeless, wearable, and disposable insulin pump “EOPatch” in the UAE. Beginning in February 2023, it becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.
 
Gulf Drug showcased its tubeless, wearable, and disposable insulin pump “EOPatch” at the 13^th Emirates Diabetes & Endocrine Congress, which is being held in Dubai International Convention & Exhibition Center from February 11^th to 13^th in Dubai. Gulf Drug sells the product throughout the UAE as ‘EOPatch’.
 
EOFlow says that this UAE launch marks the first entry of EOPatches in the Middle East. The UAE is EOFlow's second overseas sales region after Europe and is expected to serve as a bridgehead for exporting wearable insulin pump solutions to Middle East and North Africa (MENA) countries.
 
Gulf Drug is also preparing to enter other countries in the Gulf region. Currently, it plans to submit an application to Saudi Arabia for EOPatch approval and registration. Saudi Arabia is the largest diabetes market among the GCC countries. EOFlow and Gulf Drug plan to strengthen their efforts to expand the market in the Gulf region, which has a very large diabetes population.
 
“There are more than 54 million diabetic patients in the MENA region, with a high prevalence of diabetes and support programs from the government. It is highly likely to lead to great sales outcomes, and our competitor has just entered the market. We have been quick to organize the process necessary to enter a new market, from obtaining product approval to commercial launch. As expectations for our company are higher than ever, we will make our best efforts to expand into the other parts of the world as rapidly as possible,” EOFlow’s head of Marketing Joseph Seo said.
 
EOPatch is one of the only two fully disposable, wearable insulin pump solutions commercially available in the world. EOFlow announced on March 2022 that it had signed a contract with Gulf Drug to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch over the course of five years. Through this contract, EOFlow granted Gulf Drug exclusive sales rights for EOPatch in the GCC (Gulf Cooperation Council) for five years. The GCC’s six members are United Arab Emirates, Saudi Arabia, Qatar, Oman, Kuwait and Bahrain.


About EOPatch
The EOPatch Insulin Management System - tubeless, wearable and disposable ‘Patch’ insulin pump with a dedicated controller called ADM or a smartphone app Narsha, used to continuously deliver insulin in blood glucose control, provides an alternative to traditional insulin delivery methods. With its simple, wearable design, the patch provides up to three and a half days (84 hours) of continuous insulin delivery which allows a twice-a-week replacement cycle, improving the user compliance.
 
Narsha was the world’s first smartphone application to be approved for controlling insulin delivery of a wearable insulin pump. Narsha has all of the features of the existing smartphone-like controller, ‘ADM,’ as well as its cloud-based diabetes data management program, ‘EOBridge,’ eliminating the need to carry a dedicated controller at all times. Narsha can also communicate with certain blood glucose meters (BGM) via Bluetooth, providing the convenience of monitoring one’s blood glucose level and making insulin delivery decisions in one app.
 
About EOFlow
EOFlow’s mission: Providing advanced and user-friendly drug delivery solutions to all those who need them, improving life quality and contributing to improve the world to be a better place to live.
Created in 2011, EOFlow Co., Ltd. became a global provider of wearable drug delivery solutions with its EOPatch brand of products. EOFlow officially launched its EOPatch, Korea’s first and the world’s second tubeless, wearable and disposable insulin pump, in Korea in April 2021. The Company also officially launched the Android and iOS version of the smartphone app Narsha. Narsha is the world’s first smartphone app that can monitor and control insulin delivery of EOPatch. EOPatch (named ‘Glucomen Day PUMP’ in Europe) has been officially launched in Europe by EOFlow’s European partner A. Menarini Diagnostics since September 2022. EOFlow has recently launched EOPatch in the United Arab Emirates. EOFlow received regulatory approvals for EOPatch in Indonesia and submitted a 510(k) application to the U.S. FDA. EOFlow aims to actively expand into the global market.
 
About Gulf Drug
Gulf Drug’s mission: Creating and providing reliable quality and value for customers, partners and stakeholders that will improve healthcare outcomes and services.
GulfDrug LLC (Gulf Drug), headquartered in Dubai, specializes in providing quality healthcare across a broad range of services including consumer healthcare, private and institutional pharmaceutical businesses, medical equipment, medical supplies as well as veterinary care. With a background of more than 50 years of experience and a network spreading across the United Arab Emirates, Gulf Drug has established one of the largest distribution channels in the GCC and plans to sell EOPatch in the region through its local distribution network. Gulf Drug is also well known for its strong marketing strategies; it aims carry out various marketing, sales promotions to build product awareness of EOPatch.
 
Forward-Looking Statement
This press release contains forward-looking statements regarding future operating and financial performance. The predictive information may be affected by future management and contains inherent uncertainty. Actual future performance may differ significantly from the predictive information due to these uncertainties. These forward-looking statements are based on management’s current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. Any details are subject to change without prior notice due to changes in market conditions and operation strategies in the future. The Company and its employees will not be liable for any losses incurred from utilizing the information contained in this press release.

※ For any IR/PR inquiries, please email to ir.pr@eoflow.com